TIDMVAL

RNS Number : 5610Q

ValiRx PLC

01 March 2021

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Total Voting Rights and Block Listing Update

London, UK 1 March 2021: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company today updated its total voting rights disclosure position.

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, the total number of Ordinary Shares in issue is 65,049,156. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

The figure of 65,049,156 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Warrant Update

As at the date of this announcement, 8,951,399 warrants at 13p have been exercised bringing gross proceeds of circa GBP1,163,682 (of which circa GBP21,666 were received in February 2021) to the Company and 83,333 warrants exercisable at 13p are outstanding. The aggregate number of warrants exercised at 13p in the month of March 2021 (and subject to the block listing announced on 19 August 2020) will be notified in the monthly total voting rights update on 1 April 2021.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information please contact:

 
 ValiRx plc                                  Tel: +44 024 7679 
                                               6496 
                                               www.valirx.com 
  Suzanne Dilly                               Suzanne.Dilly@valirx.com 
 
   Cairn Financial Advisers LLP (Nominated     Tel: +44 (0) 20 7213 
   Adviser)                                    0880 
   Liam Murray / Jo Turner / Ludovico 
   Lazzaretti 
 
   Peterhouse Capital Limited (Sole Broker)    Tel: +44 (0) 20 7469 
   Duncan Vasey / Lucy Williams / Eran         0930 
   Zucker 
 
   Optimum Strategic Communications            Tel: +44 (0) 20 8148 
   Supriya Mathur/ Shabnam Bashir              3040 
                                               valirx@optimumcomms.com 
 
 
 About ValiRx 
 ValiRx accelerates the development 
 of treatments in oncology and 
 women's health to improve patient 
 lives. We provide the scientific, 
 financial and commercial framework 
 to enable rapid translation 
 of innovative science into 
 clinical development. 
 
 With our extensive and proven 
 experience in research and 
 drug development, we select 
 and incubate promising novel 
 drug candidates and guide them 
 through an optimised process 
 of development, from pre-clinical 
 studies to clinic and investor-ready 
 assets. 
 
 Integrating science and business 
 We connect diverse disciplines 
 across scientific, technical 
 and commercial domains, with 
 the promise of achieving a 
 more streamlined, less costly, 
 drug development process. We 
 work closely with our selected 
 collaborators and leverage 
 the combined expertise required 
 for science to advance. 
 
 Lead candidates from our portfolio 
 are out-licenced or partnered 
 with investors through ValiRx 
 subsidiary companies for further 
 clinical development and commercialisation. 
 https://www.valirx.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREALAKALDFEFA

(END) Dow Jones Newswires

March 01, 2021 02:00 ET (07:00 GMT)

Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Valirx.
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Valirx.